Concepedia

J. Tambiah

JT

16

Publications

1.1K

Citations

13

H-Index

2001

Active since

Affiliations

Samumed (United States)(Current)

Tufts Medical Center

Cornell University

University of Maryland, Baltimore

University of California, Davis

J. Tambiah is an author at Samumed (United States) specializing in medicine, osteoarthritis, and orthopaedics.

ORCID

Top concepts

Publications per year

2001–2022

16

Publications

16

A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee

V. Deshmukh, Haide Hu, Charlene F. Barroga et al. · Osteoarthritis and Cartilage · 2017 · 218 citations · Full text

Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment

V. Deshmukh, Alyssa L. O'Green, Carine Bossard et al. · Osteoarthritis and Cartilage · 2019 · 185 citations · Full text

Lorecivivint, a Novel Intraarticular CDC‐like Kinase 2 and Dual‐Specificity Tyrosine Phosphorylation‐Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized Trial

Timothy E. McAlindon, Allan Gibofsky, Nancy E. Lane et al. · Arthritis & Rheumatology · 2020 · 132 citations · Full text

A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study

Timothy E. McAlindon, Roy Fleischmann, Allan Gibofsky et al. · Osteoarthritis and Cartilage · 2017 · 128 citations · Full text

A Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis

T.E. McAlindon, Allan Gibofsky, Nancy E. Lane et al. · Osteoarthritis and Cartilage · 2021 · 99 citations · Full text

Rows per page

1–5 of 16